Elevance Health stock has returned 22.7% over the past year, and the latest valuation checks still lean in favor of the shares looking cheap rather than stretched. This sets up a clear question about how much of the recent news and earnings risk is already reflected in the price.

• Over the last 12 months, a 22.7% gain suggests investors have been willing to pay more for Elevance Health, even as some operational questions stay in focus.
• Upgrades to the Health OS platform can support the case for stronger long term efficiency, while the lawsuit over Medicare Advantage star ratings highlights how regulatory outcomes may affect the value investors ascribe to future cash flows.
• On Simply Wall St's broader checks, Elevance Health screens as undervalued in 5 of 6 tests, which points to the stock looking cheap across several common valuation measures here.

The stock's next move may depend on whether the current share price already captures the legal, regulatory, and growth risks that sit behind that seemingly attractive valuation picture for Elevance Health.

Does Elevance Health Look Undervalued on Earnings?

The P/E multiple is a useful way to look at Elevance Health because earnings are a key driver of how investors usually value a large, mature healthcare insurer.

Elevance Health trades on a P/E of about 17.3x, which sits well below the Healthcare industry average of roughly 25.9x and the peer group average near 43.1x. On Simply Wall St's more tailored fair P/E estimate, which factors in the company’s size, margins and risk profile, Elevance Health would trade closer to 33.3x, so the current P/E is at a sizeable discount to that benchmark as well.

Despite the recent Medicare Advantage star ratings lawsuit creating a clear regulatory overhang, the stock still trades on a P/E that is materially below both sector norms and this fair ratio estimate. Taken together, the market seems to be assigning a relatively low earnings multiple to Elevance Health compared with what these frameworks suggest.

On the P/E multiple, Elevance Health stock appears inexpensive relative to both its industry and the fair ratio estimate.

The Elevance Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Elevance Health's valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than the current price, using structured scenarios on the Community page. Each narrative links a fair valuation to a defined set of potential catalysts and risks, so you can track over time which underlying story appears to be taking shape.

Community views on Elevance Health sit on opposite sides of the fence, with one narrative seeing margin recovery potential and the other focused on policy and Medicaid risk.

Bull case: roughly fairly valued

"Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams..."

Bear case: 26% overvalued

"Even though the company is exercising disciplined pricing and investment in operational improvements, heavy exposure to government-backed business exposes Elevance Health to reimbursement risk, political uncertainty, and delays in rate alignment..."

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

The Bottom Line

Elevance Health screens as undervalued on common market multiples, even after factoring in its size, margins and risk profile. For you, the key question is whether that discount is compensation for the legal and regulatory overhang, or an opening if earnings resilience and efficiency gains from Health OS hold up. The crux of the bull versus bear debate is whether Elevance Health earns back a higher P/E over time or whether policy and reimbursement pressures keep the stock sitting on a lower multiple for longer.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.